Patent · US Expired

In-vitro transcription processes for screening natural products and other chemical substances

US6174722A · kind A · utility

1Cited by

1References

8Claims

0Family size

Assignee

Aventis Pharma Deutschland GmbH · DE

Inventors

Bernd Kirschbaum · Mainz, DE
Wilhelm Stahl · Idstein, DE
Irvin Winkler · Liederbach, DE
Michael Meisterernst · Eichenau, DE

Key dates

Filing date	Mar 11, 1998
Grant date	Jan 16, 2001
Priority date	—
Expiry date	Mar 11, 2018

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q1/6897
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

An process for analyzing transcription which can be automated and which is suitable for bulk screening. The process involves transcribing a DNA sequence using a nuclear extract, which can be complemented or fully replaced by exogenous transcription factors and/or cofactors; optionally removing the proteins of the reaction mixture; binding the resulting transcript to a solid matrix; removing the excess labeled nucleotides; and determining the amount of labeled transcript. Methods of using the inventive process to identify compounds having a selective effect on gene expression.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.